Skip to content

ten23 health announces expansion with the launch of quality control services

Share this article

ten23 health® announces the launch of “quality control” service offerings in Switzerland for release and stability testing of clinical and commercial sterile drug products according to international cGMP standards. The new quality control division will be set up in Basel and Visp.


In Basel ten23 health® will offer physico-chemical testing, including content, purity, identity and pharmacopeial methods to ensure the release and stability of sterile, pharmaceutical Drug Products for clinical and commercial use. These services will be integrated with the pharmaceutical development service provided by ten23 in Basel.


Simultaneously, in Visp, the company will provide microbiological quality control services, encompassing environment monitoring and final product microbiological testing, including sterility. The microbiological services in Visp will be co-located with the operations of the sterile product manufacturing and in the future building, constructing further sterile filling capacity.


ten23 health®  already has hired experts into critical roles for our QC services, and these new service offerings will also bring additional potential for future jobs in both the Basel and Visp regions. The biotech company expects to be operational and GMP ready for quality control services by Q2/2024.


It provides fully integrated services that cover development, manufacturing and testing: formulation development, DP process development, analytical method development, packaging and device selection support and integration, special testing for Particulates and Container Closure Integrity, stability testing, GMP fill & finish and GMP release and stability testing.


“We are excited to announce the expansion and the launch of our quality control services,” said Hanns-Christian Mahler, CEO of ten23 health®. “By adding these services, we aim to streamline the development, testing and manufacturing processes for our clients, enabling them to focus on their core competencies while we can handle their needs for pharmaceutical development, sterile manufacturing and testing. We are confident that our expanded offerings will provide immense value to our clients and contribute to the speed and regulatory and commercial success of their pharmaceutical endeavours to the benefit of their patients.”


About ten23 health®

ten23 health®, employes 74 people in Basel, and 96 in Visp, Switzerland. The company develops, manufacture, and test modern medicines. It support its clients in developing differentiated, stable, usable, and safe injectable treatment options for patients. The premises in Visp, Switzerland, is a world leader in the sterile production of complex pharmaceutical dosage forms and a wholly owned co-subsidiary of ten23 health.


Source: press release